- BioFactura, Inc. has launched Capitol Biologics, a new CDMO division focused on early-phase clinical manufacturing and process development.
- The unit is located in the BioHealth Capital Region, serving emerging biotech companies and U.S. government agencies.
BioFactura, Inc., a clinical-stage biopharmaceutical company, has announced the creation of Capitol Biologics, a new Contract Development and Manufacturing Organization (CDMO) division. The unit will provide process development, early-phase clinical manufacturing, and analytical services to biotechnology firms and government partners.
Capitol Biologics will operate within the BioHealth Capital Region and the I-270 Biotech Corridor near Washington, DC. Its location offers access to pharmaceutical hubs, government facilities, and leading research institutions.
Building on BioFactura’s 20 years of expertise, the division will deliver phase-appropriate contract manufacturing solutions for monoclonal antibodies, recombinant proteins, and other complex biologics. Services will cover cell line development, process optimisation, GMP production, and analytical testing, all under a quality system aligned with FDA, EMA, and ICH standards.
Darryl Sampey, President and CEO of BioFactura, said: “Transforming the biopharma development engine that BioFactura has built over the past 20 years into a pure-play service organisation provides an incomparable value to early-stage ventures and initiatives.”
The new CDMO aims to support both private biotech innovators and public health initiatives, strengthening national preparedness while providing emerging companies with access to specialised biologics development and manufacturing capabilities.
